Clinical Trials · NCT01928329
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Yale University
- Enrollment
- 79
- Start date
- Sep 2013
- Locations
- 8 sites, United States
- Primary endpoint
- Change From Baseline in HbA1c Levels